18:57 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro, cell culture and mouse studies suggest inhibiting the DNAJ/Hsp70 chaperone axis could help treat castration-resistant prostate cancer (CRPC). Screening of a library of chalcone analogs and testing in cell-based signaling assays...
18:04 , Jul 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies identified a compound that recruits androgen receptor to IAP for proteasomal degradation that could help treat prostate cancer. The compound consisted of an androgen receptor ligand and a peptidomimetic of...
07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Androgen receptor

Cancer INDICATION: Prostate cancer Cell culture and mouse studies identified a peptoid-based androgen receptor antagonist that could help treat prostate cancers resistant to Xtandi enzalutamide and other androgen receptor antagonists. In multiple human prostate cancer cell lines,...
01:07 , Apr 30, 2016 |  BC Extra  |  Top Story

Medivation rejects Sanofi bid

To little surprise, Medivation Inc. (NASDAQ:MDVN) rejected an unsolicited bid from Sanofi (Euronext:SAN; NYSE:SNY) to acquire the company for $52.50 per share in cash, or about $9.3 billion. Sanofi made its offer public on Thursday...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Clinical News

Xtandi enzalutamide regulatory update

Medivation and Astellas said EMA’s CHMP recommended approval of a Type II variation for Xtandi enzalutamide to update the label to include Phase II data comparing Xtandi vs. Casodex bicalutamide in patients with metastatic...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Xtandi enzalutamide regulatory update

Astellas and Medivation said FDA accepted for review an sNDA for Xtandi enzalutamide to update the label to include Phase II data comparing Xtandi vs. Casodex bicalutamide in patients with metastatic castration-resistant prostate cancer...
08:00 , Dec 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-124 (miR-124)

Cancer INDICATION: Prostate cancer Mouse studies suggest miR-124 could help treat castration-resistant prostate cancer (CRPC). In human prostate cancer cell lines, miR-124 plus Xtandi enzalutamide or Casodex bicalutamide decreased proliferation compared with either agent alone. In a...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Xtandi enzalutamide: Phase II data

Top-line data from the double-blind, U.S. Phase II STRIVE trial in 396 patients with CRPC showed that once-daily 160 mg oral Xtandi met the primary endpoint of improving median PFS vs. once-daily 50 mg oral...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Xtandi enzalutamide: Additional Phase II data

Additional data from the double-blind, international Phase II TERRAIN trial in 375 patients with metastatic prostate cancer whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analog therapy or following surgical castration...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Clinical News

Xtandi enzalutamide: Phase II data

Top-line data from the double-blind, international Phase II TERRAIN trial in 375 patients with metastatic prostate cancer whose disease progressed despite treatment with a luteinizing hormone-releasing hormone (LHRH) analog therapy or following surgical castration...